BioXcel Therapeutics Inc

General ticker "BTAI" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $17.6M

BioXcel Therapeutics Inc does not follow the US Stock Market performance with the rate: -41.2%.

Estimated limits based on current volatility of 8.8%: low 0.30$, high 0.36$

Factors to consider:

  • Current price 71.6% below estimated low
  • Earnings for 6 months up through Q2 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [1.22$, 4.30$]
  • 2024-12-30 to 2025-12-30 estimated range: [0.90$, 2.88$]

Financial Metrics affecting the BTAI estimates:

  • Negative: Non-GAAP EPS, $ of -6.15 <= 0.10
  • Negative: Operating profit margin, % of -99.20 <= 1.03
  • Negative: Operating cash flow per share per price, % of -61.01 <= 2.35
  • Negative: negative Net income
  • Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85

Similar symbols

Short-term BTAI quotes

Long-term BTAI plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $0.00MM $0.38MM $1.38MM
Operating Expenses $106.94MM $160.02MM $173.16MM
Operating Income $-106.94MM $-159.65MM $-171.78MM
Non-Operating Income $0.00MM $-6.11MM $-7.27MM
Interest Expense $0.00MM $8.21MM $13.31MM
R&D Expense $52.71MM $91.24MM $84.33MM
Income(Loss) $-106.93MM $-165.76MM $-179.05MM
Profit(Loss) $-106.93MM $-165.76MM $-179.05MM
Stockholders Equity $221.67MM $76.78MM $-56.51MM
Inventory $0.00MM $1.99MM $1.99MM
Assets $239.44MM $205.85MM $73.70MM
Operating Cash Flow $-82.15MM $-135.34MM $-155.01MM
Capital expenditure $0.45MM $0.14MM $0.02MM
Investing Cash Flow $-0.45MM $-0.14MM $-0.02MM
Financing Cash Flow $102.45MM $96.24MM $26.52MM
Earnings Per Share* $-4.04 $-6.13 $-6.15

* EPS are Split Adjusted, recent splits may be reflected with a delay.